Related Experiment Videos
Iron Deficiency Treatment in Patients with Heart Failure
Ewa A Jankowska1,2, Marcin Drozd3,4, Piotr Ponikowski4,5
1Laboratory for Applied Research on Cardiovascular System, Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland. ewa.jankowska@umed.wroc.pl.
Insights
Iron deficiency (ID) is a common issue in heart failure (HF) patients. Intravenous iron effectively replenishes iron stores, improving HF symptoms and quality of life.
Area of Science:
- Cardiology
- Hematology
- Internal Medicine
Background:
- Iron deficiency (ID) is a significant global health concern, linked to disability and mortality.
- ID is a frequent and serious comorbidity in heart failure (HF) patients, irrespective of anemia status.
- Evidence from clinical trials (FAIR-HF, CONFIRM-HF) and epidemiology highlights ID as a key therapeutic target in symptomatic HF with LVEF ≤45%.
Purpose of the Study:
- To evaluate the role of iron deficiency as a therapeutic target in heart failure.
- To assess the efficacy and safety of intravenous iron supplementation in heart failure patients.
Main Methods:
- Review of clinical trials, including FAIR-HF and CONFIRM-HF.
- Analysis of epidemiological data on iron deficiency in heart failure.
- Evaluation of intravenous iron supplementation for iron repletion.
Main Results:
- Intravenous iron supplementation is safe and effective for iron repletion.
- Treatment with intravenous iron improves clinical status, exercise capacity, and quality of life in HF patients.
- Ongoing trials investigate the potential of this therapy to reduce HF hospitalizations and cardiovascular death.
Conclusions:
- Iron deficiency is a critical therapeutic target in symptomatic heart failure patients.
- Intravenous iron supplementation offers significant benefits for heart failure management.
- Further research is underway to confirm the long-term impact of intravenous iron on HF outcomes.
Abstract:
Iron deficiency (ID) is one of the major risk factors for disability and mortality worldwide, and it was identified as a common and ominous comorbidity in patients with heart failure (HF), both with and without anaemia. Based on two clinical trials (FAIR-HF and CONFIRM-HF) and other epidemiological evidence, ID has been recognized as an important therapeutic target in symptomatic patients with HF and LVEF ≤45%.Intravenous iron supplementation has been demonstrated to be safe and effective for iron repletion and related with an improvement in clinical status, exercise capacity, and quality of life. Ongoing trials are testing the hypothesis that such a therapy may also reduce the risk of HF hospitalizations and cardiovascular death.